Growth Hormone Secretagogues: Complete Research Comparison

The GHS Landscape

Growth hormone secretagogues (GHS) are compounds that stimulate GH release from the pituitary gland. They fall into two main mechanistic categories: GHRH analogs (which act on the GHRH receptor) and GHRPs/ghrelin mimetics (which act on the GHS receptor, also known as the ghrelin receptor). Understanding these two pathways and how they interact is fundamental to GH research.

GHRH Analogs

GHRH analogs mimic the action of endogenous growth hormone-releasing hormone, stimulating somatotroph cells in the anterior pituitary to release GH:

| Compound | Half-Life | GH Pulse Amplitude | Notes | |----------|-----------|-------------------|-------| | Native GHRH(1-44) | ~7 minutes | Moderate | Reference compound | | Sermorelin (GHRH 1-29) | ~10-20 min | Moderate | Shortest active fragment | | CJC-1295 no DAC | ~30 min | Moderate-High | Modified for stability | | CJC-1295 w/ DAC | ~8 days | High | Albumin binding extends half-life | | Tesamorelin | ~26 min | High | FDA-approved for HIV lipodystrophy |

GHRH analogs preserve the pulsatile nature of GH release and require intact somatostatin tone to function — they amplify existing GH pulses rather than creating new ones.

GHRPs and Ghrelin Mimetics

GHRPs act on the GHS-R1a receptor, stimulating GH release through a different pathway that is synergistic with GHRH:

| Compound | Half-Life | GH Pulse | Cortisol/Prolactin | Hunger | |----------|-----------|----------|-------------------|--------| | GHRP-6 | ~15-20 min | High | Significant | Strong | | GHRP-2 | ~15-20 min | Very High | Moderate | Moderate | | Hexarelin | ~15-20 min | Very High | Significant | Mild | | Ipamorelin | ~2 hours | Moderate-High | Minimal | Minimal | | MK-677 | ~24 hours | Sustained | Mild | Moderate |

Ipamorelin is the most selective GHRP, with minimal effects on cortisol and prolactin, making it the preferred choice for research requiring clean GH stimulation without HPA axis activation.

The Synergy Principle

The most important concept in GHS research is the synergy between GHRH analogs and GHRPs. When administered together, they produce GH release 5–10 times greater than either compound alone. This synergy occurs because:

1. GHRH increases the number of somatotrophs ready to release GH
2. GHRPs amplify the release signal through a separate receptor
3. GHRPs also suppress somatostatin, removing the brake on GH release

This is why CJC-1295 + Ipamorelin is the most commonly studied combination in GH research.

Pulsatility Considerations

GH is naturally released in pulses, primarily during sleep. Maintaining pulsatility is important for research validity — continuous GH elevation (as seen with exogenous GH) produces different effects than pulsatile release. Short-acting GHRPs and GHRH analogs preserve pulsatility; CJC-1295 with DAC produces a more sustained "GH bleed" that partially blunts pulsatility.

IGF-1 as a Research Endpoint

Most GHS research uses serum IGF-1 as the primary endpoint, since IGF-1 is produced by the liver in response to GH and reflects integrated GH exposure over time. IGF-1 has a half-life of ~15 hours, making it a stable and practical biomarker. GH itself has a half-life of ~20 minutes and is difficult to measure accurately.

Research Applications by Compound

| Research Goal | Recommended Compound | |---------------|---------------------| | Clean GH pulse research | Ipamorelin | | Maximum GH stimulation | GHRP-2 or Hexarelin | | Long-acting GH research | CJC-1295 w/ DAC or MK-677 | | Pulsatile GH research | CJC-1295 no DAC + Ipamorelin | | HPA axis interaction study | GHRP-6 or Hexarelin |

Key Research Takeaways

The GHS landscape offers researchers a rich toolkit for studying GH physiology. The choice of compound depends on the specific research question — pulsatility, potency, selectivity, and half-life all vary significantly across the class. The GHRH + GHRP synergy principle is one of the most robust findings in GH research and should inform the design of any GH stimulation study.